\
&
Contact us
\
&
Contact us
The National Contact Points are support structures established by Member States and Associated Countries (AC) and recognized by the European Commission to help participants to access the different opportunities in the Horizon Europe programme and Digital Europe programme.
NCPs provide on the ground advice to potential applicants and beneficiaries, through the project life cycle, in a manner that would be impossible for the Commission and its Agencies acting alone.
In Belgium NCPs have been established per region. NCP Flanders provides free of charge information and advice to all stakeholders located in Flanders (enterprises, institutes, non-profit-organisations, universities, university colleges,...) and to all Flemish public institutions located anywhere in Belgium. NCP Flanders is a cooperation between the Research Foundation Flanders (FWO), and Flanders Innovation & Entrepreneurship (VLAIO).
NCP Flanders can help to:
Are you a staff member of a university, university of applied science or research organisation based in Flanders?
Several Flemish institutes and organisations offer support services for European funding for research and innovation, also known as European Liaison offices. Your organisation might have such an office in place, which is your first contact point. You can consult a (non-exhaustive) list with the necessary contact information here.
Are you a Belgian stakeholder not located in Flanders?
Since in Belgium NCP services are regionalised, there are 4 other NCP organisations responsible for other stakeholder groups:
Related link: Looking for someone specific? Check the most up-to-date list of European Horizon Europe NCP advisors or of European Digital Europe NCP advisors on the Funding and Tenders Portal of the Commission.
To promote equal and consistent support, the Commission has set out a common reference for NCPs in all participating countries. Find the common reference for NCPs here .
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
